title: Alefacept therapy for nephrogenic systemic fibrosis: a case series.
abstract: Nephrogenic systemic fibrosis (NSF) is a recently described systemic fibrosing disorder that develops in the setting of renal insufficiency. Exposure to gadolinium has been implicated in its development. While the primary manifestations are cutaneous, systemic fibrosis can also occur. Several anecdotal reports of successful treatment have been reported, but there is no consistently efficacious therapy. We report the improvement or stabilization of cutaneous disease in three patients with NSF using alefacept therapy.
authors.affiliation: Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
authors.forename: Maria R
authors.initials: MR
authors.lastname: Robinson
authors.forename: Shannon B
authors.initials: SB
authors.lastname: Routhouska
authors.forename: Raj M
authors.initials: RM
authors.lastname: Paspulati
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
mesh_terms: D000368:Aged; D000077944:Alefacept; D003287:Contrast Media / Q000009:adverse effects; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D054989:Nephrogenic Fibrosing Dermopathy / Q000188:drug therapy* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003287:Contrast Media; D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D005682:Gadolinium; D000077944:Alefacept